Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $106.4 million, exceeding the top of the guided range, while adjusted EBITDA was significantly ahead of guidance [15][16] - The company generated positive free cash flow of approximately $3.1 million, with cash, cash equivalents, and marketable securities totaling over $234 million at the end of the quarter [16] - The net cash position improved by nearly $20 million compared to the same time last year, reaching over $23 million relative to convertible notes [16] Business Line Data and Key Metrics Changes - The selling season remains strong, with a concentration of activity in summer and fall, and a notable new deal won in the expert medical opinion space [11][12] - The company is diversifying across segments, including strategic, enterprise, health plans, and government, which is seen as a strength [12] Market Data and Key Metrics Changes - There is strong demand across all core platforms, including expert medical opinion and primary care, particularly in the health plan space [25][26] - The employer segment is experiencing increased pressure on ROI guarantees due to rising healthcare costs, which aligns with the company's strengths [32] Company Strategy and Development Direction - The company is focused on building a collaborative ecosystem that shares longitudinal data to improve healthcare experiences and lower costs [10] - Management emphasizes the importance of profitability and sustainable growth, with a commitment to managing costs effectively while driving revenue [18][19] Management's Comments on Operating Environment and Future Outlook - Management remains bullish about the market's strength and the company's ability to execute its vision [14] - The company expects to continue generating positive cash flow and is focused on achieving profitability while balancing revenue growth [18][19] Other Important Information - The company is taking steps to improve member experience and achieve performance guarantees set with customers [13] - The guidance for Q3 includes revenue in the range of $104 million to $107 million and adjusted EBITDA loss between $3 million and $5 million [17] Q&A Session Summary Question: How is navigation spotting relative to other corporate priorities this year? - Management noted that trends like GLP-1s drive demand for advocacy and primary care, highlighting the unique opportunity to bundle services [22] Question: How is visibility shaping up for the selling season? - Management indicated strong demand across various segments, with deployment timeframes varying based on customer needs [25][26] Question: What observations can be shared regarding employer benefits this year? - Management mentioned that employers are focusing more on ROI guarantees due to rising healthcare costs, which plays to the company's strengths [32] Question: Can you provide details on utilization-based revenue in the quarter? - Utilization-based revenue was around 32% of total revenue for the quarter, consistent with prior trends [36] Question: How much of the book is up for renewal this year? - Management expects retention rates to remain above 90%, indicating strong customer satisfaction and value [39] Question: Can you elaborate on the trusted partners ecosystem? - The company integrates with a variety of condition-oriented solutions, enhancing clinical engagement and driving better ROI for customers [78]

October 2024 NASDAQ: ACCD Accolade Inc. Investor Presentation | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Accolade (ACCD) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.35, delivering a surprise of 27.08%.Over the last four quarters, the company has surpassed conse ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ FORM 10-Q ______________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39348 ACC ...

On October 8, 2024, Accolade Inc (ACCD, Financial) released its 8-K filing detailing the financial results for the fiscal second quarter ending August 31, 2024. Accolade Inc, a company offering technology-enabled solutions to navigate the healthcare system, reported a revenue of $106.4 million, exceeding the analyst estimate of $105.01 million. The company continues to focus on its physician-led advocacy approach to enhance healthcare experiences for its members.Financial Performance and Challenges Accolade ...

Exhibit 99.1 Three months ended August 31, Accolade Announces Results for Fiscal Second Quarter 2025 SEATTLE, October 8, 2024 -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamenta ...

Accolade Inc (ACCD, Financial) is set to release its Q2 2025 earnings on Oct 8, 2024. The consensus estimate for Q2 2025 revenue is $105.01 million, and the earnings are expected to come in at -$0.44 per share. The full year 2025's revenue is expected to be $466.97 million and the earnings are expected to be -$1.11 per share. More detailed estimate data can be found on the Forecast page.Accolade Inc (ACCD, Financial) Estimates TrendsOver the past 90 days, revenue estimates for Accolade Inc (ACCD) for the fu ...

Accolade, Inc. ACCD will release earnings results for its second quarter, before the opening bell on Tuesday, Oct. 8. Read This Next: Quote.Descriptions.analyst-ratings. Analysts expect the Seattle, Washington-based company to report a quarterly loss at 44 cents per share, versus a year-ago loss of 43 cents per share. Accolade is projected to post quarterly revenue of $105.01 million, according to data from Benzinga Pro. On June 27, Accolade reported first-quarter financial results and issued worse-than-exp ...

Group 1 - Accolade, Inc. will release its fiscal second quarter 2025 financial results on October 8, 2024, before market open [1] - A conference call to review the results will take place at 8:00 a.m. E.T. on the same day [1] - The company provides a range of personalized healthcare solutions, including virtual primary care, mental health services, and care navigation [3] Group 2 - Accolade's platform is designed to enhance healthcare experiences through predictive engagement and proactive care, aiming to improve outcomes and reduce costs [3] - The company has consistently received consumer satisfaction ratings exceeding 90% [3]

INCLINE VILLAGE, Nev., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Tri Pointe Homes® (NYSE: TPH), one of the largest homebuilders in the U.S., announced today that it has earned coveted inclusion on the 2024 PEOPLE® Companies That Care® list from PEOPLE Magazine and Great Place To Work® and the 2024 Fortune Best Workplaces in Construction™ List from Fortune magazine and Great Place to Work®. The accolades reflect Tri Pointe’s ongoing dedication to fostering a workplace culture that prioritizes care, innovation, and ...